The　abnormal　aggregation　of　A　beta　has　been　considered　one　of　the　primary　causative　factors　for　Alzheimer＇s　disease.　Diverse　molecular　entities　have　been　developed　to　mitigate　the　formation　of　toxic　A　beta　aggregates　within　the　brain　by　inhibiting　A　beta　aggregation.　Recognizing　that　many　FDA-approved　drugs　are　derived　from　natural　products,　we　present　a　summary　of　recent　discoveries　involving　natural　product　molecules　with　inhibitory　effects　on　A　beta　aggregation.　By　consolidating　these　findings,　our　review　offers　researchers　a　concise　overview　of　the　latest　advancements　in　natural　product-based　interventions　for　Alzheimer＇s　disease.